glp-1 ibd 🚨 RA use in is rising fast In this 14-month repeated survey of patients with IBD: 📈 GLP-1 RA use rose 5-fold ⚖️ Median BMI fell from 35.3 → 31.2 Efficacy and Safety of GLP-1

Mishra, N

Major semaglutide weight loss trials (STEP 14) did not measure cortisol as a primary or secondary outcome

But it is not a casual intervention

Overall Safety and Tolerability Assessment The primary safety conclusion from the comprehensive trial program was unambiguous: AOD-9604 displayed a very good safety and tolerability profile indistinguishable from placebo

10.3727/096368914x678508 [DOI] [PubMed] [Google Scholar] DellaValle B., Brix G

Additionally, a randomized controlled trial revealed that a combination of flavan-3-ols and isoflavones enhanced insulin sensitivity and lipoprotein profiles compared to placebo, further lowering the estimated 10-year CVD risk in women with type 2 diabetes (Peter et al., 2012)